Brain metastases are a very common manifestation of cancer that have historically been
approached as a single disease entity given the uniform association with poor clinical …

This review focuses on the management of brain metastases. The four main modes of
therapy are discussed: whole brain radiation therapy (WBRT), surgery, radiosurgery, and …

BACKGROUND: Lung cancer is the leading cause of cancer deaths in most countries. In
patients with metastases, such as the brain, the 1-year survival is 10% and most of these …

BACKGROUND: Brain metastases (BM) represent one of the most common challenges
related to non-small cell lung cancer (NSCLC), with evolving treatment strategies. We have …

Gefitinib—a specific inhibitor of epidermal growth factor receptor (EGFR)-associated tyrosine
kinase—has demonstrated efficacy in a subgroup of patients with non-small-cell lung …

Brain metastases (BM) are the most common intracranial tumors and their incidence is
increasing. Untreated brain metastases are associated with a poor prognosis and a poor …

Central nervous system (CNS) metastasis refers to the spread of a systemic cancer from an
initial primary site within the body to the brain, spinal cord, or the adjoining layers that …

BACKGROUND: Only 15% of patients with non-small cell lung cancer (NSCLC) treated with
oral epidermal growth factor tyrosine kinase inhibitor gefitinib, as a second-line therapy have …

The incidence of brain metastasis (BM) is high in patients with non-small-cell lung cancer.
Available standard therapeutic options, such as whole-brain radiation therapy and systemic …

Abstract About 20% to 40% of patients with non-small cell lung cancer (NSCLC) will develop
brain metastases during the natural course of their disease. The prognosis for such patients …